文献类型：期刊文献

英文题名：A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma

作者：Tang, Huan[1];Miao, Xin[2];Yu, Cheng[1,3];Chai, Changpeng[1,4];Su, Yuanhui[1];Li, Lu[4];Yi, Jianfeng[5,6];Ye, Zhenzhen[1,6];Miao, Long[1,4];Wang, Zhengfeng[1,4];Zhang, Hui[1,7];Xu, Hao[2,8];Zhou, Wence[1,7]

第一作者：Tang, Huan

通信作者：Zhang, H[1];Zhou, WC[1];Xu, H[2];Zhang, H[3];Zhou, WC[3];Xu, H[4]

机构：[1]Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China;[2]Zhejiang Chinese Med Univ, Sch Clin Med 1, Hangzhou 310006, Peoples R China;[3]Lanzhou Univ, Hosp 2, Dept Anesthesiol, Lanzhou 730000, Peoples R China;[4]Lanzhou Univ, Hosp 1, Dept Gen Surg 4, Lanzhou 730000, Peoples R China;[5]Lanzhou Univ, Clin Med Sch 1, Lanzhou 730000, Peoples R China;[6]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730000, Peoples R China;[7]Lanzhou Univ, Hosp 2, Dept Gen Surg, 82 Cuiyingmen, Lanzhou 730000, Gansu, Peoples R China;[8]Zhejiang Prov Hosp Tradit Chinese Med, Dept Hepatobiliary Surg, Hangzhou 310006, Peoples R China

第一机构：Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Clin Med Sch 2, Lanzhou 730000, Peoples R China;[2]corresponding author), Zhejiang Chinese Med Univ, Sch Clin Med 1, Hangzhou 310006, Peoples R China;[3]corresponding author), Lanzhou Univ, Hosp 2, Dept Gen Surg, 82 Cuiyingmen, Lanzhou 730000, Gansu, Peoples R China;[4]corresponding author), Zhejiang Prov Hosp Tradit Chinese Med, Dept Hepatobiliary Surg, Hangzhou 310006, Peoples R China.

年份：2024

卷号：14

期号：1

外文期刊名：SCIENTIFIC REPORTS

收录：;Scopus(收录号：2-s2.0-85190875633);WOS:【SCI-EXPANDED(收录号:WOS:001206473300005)】；

基金：We would like to thank Bullet Edits (http://www.bulletedits.cn) for English language editing of the manuscript.

语种：英文

外文关键词：Pancreatic cancer; Cell line; Chemotherapy; Multidrug resistance; Transplanted tumour

摘要：Chemotherapy resistance poses clinical challenges in pancreatic cancer treatment. Developing cell lines resistant to chemotherapy is crucial for investigating drug resistance mechanisms and identifying alternative treatment pathways. The genetic and biological attributes of pancreatic cancer depend on its aetiology, racial demographics and anatomical origin, underscoring the need for models that comprehensively represent these characteristics. Here, we introduce PDAC-X2, a pancreatic cancer cell line derived from Chinese patients. We conducted a comprehensive analysis encompassing the immune phenotype, biology, genetics, molecular characteristics and tumorigenicity of the cell line. PDAC-X2 cells displayed epithelial morphology and expressed cell markers (CK7 and CK19) alongside other markers (E-cadherin, Vimentin, Ki-67, CEA and CA19-9). The population doubling time averaged around 69 h. In vivo, PDAC-X2 cells consistently maintained their tumorigenicity, achieving a 100% tumour formation rate. Characterised by a predominantly tetraploid karyotype, this cell line exhibited a complex genetic markup. Notably, PDAC-X2 cells demonstrated resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil and oxaliplatin. In conclusion, PDAC-X2 presents an invaluable preclinical model. Its utility lies in facilitating the study of drug resistance mechanisms and the exploration of alternative therapeutic approaches aimed at enhancing the prognosis of this tumour type.